MedTrace Logo

Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis

NCT05530291 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85259

Last updated 2024-11-07

No results posted yet for this study

Summary

This study consists of two phases. The purpose of phase 1 is to identify incidence and patterns of erythropoiesis-stimulating agent (ESA) hyporesponsiveness and its associated factors in ESA treated patients. The purpose of phase 2 to identify outcomes associated with ESA hyporesponsiveness. Key aspects of the phase 2 study design will entirely depend on the results from phase 1.

Conditions

Interventions

OTHER

Non-interventional

Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs

Sponsors & Collaborators

  • Astellas Pharma Global Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Global Development, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-18
Primary Completion
2022-11-22
Completion
2022-11-22

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05530291 on ClinicalTrials.gov